close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MEI Pharma, Inc. - Common Stock (NQ:MEIP)

3.070 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MEI Pharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma Announces Closing of Public Offering of Common Stock
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma Announces Pricing of Public Offering of Common Stock
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma Announces Proposed Public Offering of Common Stock
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma to Host Webcast on November 30, 2021 at 8:00 a.m. ET Reporting Data from Ongoing Global Phase 2 TIDAL Study of Zandelisib in Patients with Follicular Lymphoma
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma Appoints Biotechnology Executive Sujay Kango to its Board of Directors
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma Reports First Quarter Fiscal Year 2022 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma and Kyowa Kirin receive Orphan Drug Designation for Zandelisib for the Treatment of Follicular Lymphoma
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma Announces Acceptance of Three Abstracts for Presentation at the 63rd Annual American Society of Hematology Annual Meeting
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
News headline image
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today